Skip to content

Study · Not a test of the peptide alone · 2018

7 results

Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.

Wang F, Li B, Fu P, Li Q, Zheng H, Lao X

International journal of pharmaceutics19 Jun 2018Cited by 16 (Europe PMC)

PMID29933059 (opens in a new tab)DOI10.1016/j.ijpharm.2018.06.041 (opens in a new tab)PepBankPUB-29933059
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In vivo, the fusion protein Tα1-iRGD promoted T-cell activation and CD86 expression.

    In plain wordsIn animal tumor models, a modified thymosin alpha‑1 promoted T-cell activation and raised CD86.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT-cell activation and CD86 expression
    Study

    n: not reported in source

    melanoma and lung cancer in vivo models
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Tα1-iRGD can promote T-cell activation and CD86 expression
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In vivo, Tα1-iRGD had a better effect against melanoma and a stronger inhibitory effect against lung cancer than Tα1.

    In plain wordsIn animal tumor models, a modified thymosin alpha‑1 worked better against melanoma and lung cancer than thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAntitumor effect against melanoma and lung cancer
    Study

    n: not reported in source

    melanoma and lung cancer in vivo models
    Comparator
    Tα1
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    thereby exerting better effect and stronger inhibitory against melanoma and lung cancer, respectively, than Tα1 in vivo
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In vivo, Tα1-iRGD was associated with reduced tumor vessel densities.

    In plain wordsIn animal tumor models, a modified thymosin alpha‑1 was linked to fewer blood vessels in tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor vessel density
    Study

    n: not reported in source

    melanoma and lung cancer in vivo models
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    the reduced densities of tumor vessels
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Pharmacokinetics

    In vivo, Tα1-iRGD accumulated in tumors.

    In plain wordsIn animal tumor models, a modified thymosin alpha‑1 built up in tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTα1-iRGD accumulation in tumors
    Study

    n: not reported in source

    melanoma and lung cancer in vivo models
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    Tα1-iRGD accumulation in tumors.
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In hydrocortisone-induced immunosuppression models, Tα1-iRGD showed significantly better immunomodulatory activity than Tα1.

    In plain wordsIn animal immune suppression models, a modified thymosin alpha‑1 had a stronger immune effect than thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseImmunomodulatory activity in immunosuppression models
    Study

    n: not reported in source

    hydrocortisone-induced immunosuppression models
    Comparator
    Tα1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    exhibits significantly better immunomodulatory activity in immunosuppression models induced by hydrocortisone
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism

    Compared with Tα1, Tα1-iRGD attached to more B16F10 and H460 cells.

    In plain wordsIn lab tests, a modified thymosin alpha‑1 attached to more tumor cells than thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAttachment to B16F10 and H460 cells
    Study

    n: not reported in source

    B16F10 and H460 cells
    Comparator
    Tα1
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    compared with Tα1, Tα1-iRGD can attach more B16F10 and H460 cells
    1 context sentence
    Summary · context
    Herein, we designed a fusion protein Tα1-iRGD by introducing the tumor homing peptide iRGD to Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    By circular dichroism in trifluoroethanol, both Tα1 and Tα1-iRGD adopted a helical conformation.

    In plain wordsIn lab tests, thymosin alpha‑1 and the modified peptide both formed a helical shape in a trifluoroethanol solution.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableHelical conformation by circular dichroism
    Study

    n: not reported in source

    trifluoroethanol solution
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Circular dichroism spectroscopy and structural analysis results revealed that Tα1 and Tα1-iRGD both adopted a helical confirmation in the presence of trifluoroethanol, indicating the structural basis of their functions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.